Meeting
2011 ASCO Annual Meeting
Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC).
Authors
D. Jelovac
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD
D. Jelovac , D. K. Armstrong , S. Weil , M. Phillips , B. M. Schwartz , J. M. Estes , R. D. Alvarez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT00738699
Citation
J Clin Oncol 29: 2011 (suppl; abstr 5056)
Abstract #
5056
Poster Bd #
16D
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive epithelial ovarian cancer (EOC).
First Author: Kenneth H. Kim
Poster
2016 ASCO Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus either Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.
First Author: Thomas J. Herzog
Poster
2016 ASCO Annual Meeting
PISARRO: A EUTROC phase 1b study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).
First Author: Charlie Gourley
Poster
2015 ASCO Annual Meeting
EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC).
First Author: Charlie Gourley